The 30-Day Commercial Readiness Assessment: a fixed-fee review of your commercial plan, team, and launch readiness, for biotech and specialty pharma companies.
Mike Boas
Commercial Executive · Executive Advisor · Founder, Life Sciences Roundtable
35 years at AstraZeneca and biotech · $300M+ above forecast · $8B brand launched
If you're getting close to a launch, behind on your numbers, or in the middle of a reorganization, I can tell you where your organization stands and what to fix first. It takes 30 days. You get a written report and a working session with your leadership team.
The fee is $12,500, fixed: half to start, half on delivery. There's no retainer and no follow-on commitment. If you want ongoing help afterward, we'll talk about it then.
Book the assessmentResults, not adjectives. A few of the outcomes behind the 35 years:
Led AstraZeneca's biggest mature brands through loss of exclusivity when everyone expected decline. One commercial strategy across sales, marketing, access, and supply, with 500+ people.
Helped build the commercial foundation for Farxiga, aligning launch strategy across AstraZeneca and Bristol Myers Squibb teams worldwide, and leading the work that named the brand.
Redesigned AstraZeneca's Global Medical Information operating model across 20 countries, cutting agency spend by $10M, lifting content reuse 50%, and leading 90 professionals supporting a $25B+ portfolio.
Built one of the industry's first online scientific engagement platforms, growing physician reach from roughly 2,000 to more than 300,000 users across 14 countries.
The full case studies are in the executive impact summary (PDF).
I spent just over three decades at AstraZeneca, plus two years in biotech, leading sales, marketing, medical affairs, and operations across several therapeutic areas, in the U.S. and globally. I've taken products through launch, rebuilt commercial organizations, and led some very large transformations. I've seen what works and what doesn't, usually the hard way.
These days I advise life sciences companies at inflection points: a first launch, missed numbers, a reorganization. The rule I've kept from 35 years of doing this is simple: people before projects.
Member of Life Sciences Pennsylvania and BioBreak Philadelphia. Executive coursework at MIT Sloan (AI & Business Strategy) and Wharton (Medical Executive Leadership). Based outside Philadelphia; I work internationally.
More background: executive bio (PDF) · executive impact summary (PDF)
I also founded and chair Life Sciences Roundtable, a network of senior biotech and pharma consultants. It's separate from my consulting work, but it keeps me current on what's actually working across the industry. And if what you need is a specialist rather than a commercial leader, it's a good place to start.
